Open Interest and Volume Dynamics
On 25 Sep 2026, Alkem Laboratories reported an open interest (OI) of 24,991 contracts, up from 21,049 the previous day, marking an increase of 3,942 contracts or 18.73%. This notable rise in OI was accompanied by a futures volume of 14,651 contracts, reflecting active trading interest in the stock’s derivatives. The combined futures and options value stood at approximately ₹4,76,07.62 lakhs, with futures contributing ₹47,411.23 lakhs and options an overwhelming ₹5,00,99.89 lakhs, underscoring the substantial notional exposure in the market.
The underlying stock price closed at ₹5,281, hovering just 4.06% above its 52-week low of ₹5,051. This proximity to the yearly trough, coupled with a two-day consecutive decline totalling a 2.81% loss, indicates a bearish undertone prevailing among investors. The stock’s performance lagged behind the Pharmaceuticals & Biotechnology sector, which itself fell by 0.36%, and the broader Sensex index, down 0.11% on the same day.
Market Positioning and Technical Indicators
Technical analysis reveals a mixed picture for Alkem Laboratories. The stock is trading above its 20-day moving average but remains below its 5-day, 50-day, 100-day, and 200-day moving averages. This suggests short-term weakness amid longer-term resistance levels. The narrow trading range of ₹4.5 on the day further emphasises subdued volatility despite the spike in derivatives activity.
Investor participation appears to be waning, with delivery volume on 24 Sep falling sharply by 59.19% to 52,880 shares compared to the five-day average. This decline in delivery volume signals reduced conviction among long-term holders, possibly indicating a wait-and-watch stance or profit booking amid recent price falls.
Only 1% make it here. This Large Cap from the Gems, Jewellery And Watches sector passed our rigorous filters with flying colors. Be among the first few to spot this gem!
- - Highest rated stock selection
- - Multi-parameter screening cleared
- - Large Cap quality pick
Implications of the Open Interest Surge
The sharp increase in open interest alongside a moderate volume suggests fresh positions are being established rather than existing ones being squared off. Given the stock’s recent price weakness and underperformance, this build-up in OI likely reflects directional bets skewed towards bearish or hedging strategies.
Futures value of ₹47,411.23 lakhs and options value exceeding ₹5,00,99.89 lakhs indicate significant capital allocation in derivatives, which could be driven by institutional players or sophisticated traders anticipating further downside or volatility. The large options notional value also points to active put buying or call selling, common tactics to protect portfolios or speculate on declines.
Mojo Score and Analyst Ratings
Alkem Laboratories currently holds a Mojo Score of 44.0, categorised as a Sell rating by MarketsMOJO, downgraded from a Hold on 24 Sep 2026. This downgrade reflects deteriorating fundamentals or technical outlook, reinforcing the cautious stance investors should adopt. The company is classified as a mid-cap with a market capitalisation of ₹62,909.12 crores, placing it in a segment where volatility and sector-specific risks can have amplified effects.
Liquidity and Trading Considerations
The stock remains sufficiently liquid for sizeable trades, with a 2% threshold of the five-day average traded value supporting trade sizes up to ₹1.93 crores. This liquidity ensures that institutional investors can enter or exit positions without excessive market impact, which may explain the observed open interest accumulation.
Is Alkem Laboratories Ltd your best bet? SwitchER suggests better alternatives across peers, market caps, and sectors. Discover stocks that could deliver more for your portfolio!
- - Better alternatives suggested
- - Cross-sector comparison
- - Portfolio optimization tool
Sectoral and Broader Market Context
The Pharmaceuticals & Biotechnology sector has experienced modest declines recently, with Alkem Laboratories underperforming its peers by 0.77% on the day. This relative weakness, combined with the stock’s proximity to its 52-week low, suggests that sector headwinds and company-specific challenges are weighing on investor sentiment.
Given the sector’s importance in the broader market and its sensitivity to regulatory, pricing, and innovation factors, the current derivatives activity in Alkem Laboratories may be a reflection of market participants positioning for potential volatility or sector rotation.
Investor Takeaway
Investors should approach Alkem Laboratories with caution in the near term. The surge in open interest amid falling prices and declining delivery volumes points to increased speculative or hedging activity rather than confident accumulation. The downgrade to a Sell rating by MarketsMOJO further emphasises the need for prudence.
Those holding the stock may consider monitoring key technical levels, particularly the 20-day and 50-day moving averages, for signs of trend reversal or further weakness. Meanwhile, traders active in derivatives should be aware that the current positioning suggests a bias towards downside protection or bearish bets.
Overall, while the stock remains a significant mid-cap player in the pharmaceuticals sector, the current market signals and derivatives data indicate a cautious outlook with potential for continued volatility.
Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →
